

Contents

<i>List of contributors</i>	vii
<i>Acknowledgments</i>	viii
Introduction	1
<i>Nari Lee and Josef Drexl</i>	
 PART I PATENT PROTECTION FOR PHARMACEUTICAL METHODS	
1. The patentability of genetic diagnostics in US law and policy	7
<i>Rochelle C. Dreyfuss</i>	
2. Patentability of pharmaceutical innovations: the European perspective	54
<i>Rainer Moufang</i>	
3. Patentability of medical methods in Japan	85
<i>Nari Lee</i>	
 PART II DATA EXCLUSIVITY AND PATENT TERM EXTENSION: CONVERGENCE OR DIVERGENCE	
4. Patent term restoration and non-patent exclusivity in the US	111
<i>Margo A. Bagley</i>	
5. Clinical data, data exclusivity and private investment protection in Europe	141
<i>Christian R. Fackelmann</i>	
6. Patent term extension in Japan: an academic and comparative perspective	183
<i>Ryoko Iseki</i>	
7. Recent UK case law on supplementary protection certificates	207
<i>Richard Arnold</i>	
8. Patent term extension in Japan: focusing on the <i>Pacif Capsule</i> decision	220
<i>Toshiaki Imura</i>	

PART III BALANCING INCENTIVES AND COMPETITION IN EUROPE

- | | |
|---|-----|
| 9. Strategic patenting by the pharmaceutical industry: towards a concept of abusive practices of protection
<i>Hanns Ullrich</i> | 241 |
| 10. Anticompetitive marketing in the context of pharmaceutical switching in Europe
<i>Bengt Domeij</i> | 273 |
| 11. <i>AstraZeneca</i> and the EU sector inquiry: when do patent filings violate competition law?
<i>Josef Drexler</i> | 290 |
| <i>Index</i> | 323 |